Pharmaceuticals

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmu...

2024-03-12 08:00 1749

SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Milestone Coincides with SK Biopharmaceuticals' Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide SEOUL, South Korea and ROME, March 12, 2024 /PRNewswire/ -- SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous system (CN...

2024-03-12 08:00 1450

Appointment of Dr Darren Patti to Group Chief Operating Officer

MELBOURNE, Australia, March 12, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr.Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024. Dr. Patti joined Telix in March 2021 to lead the Company'...

2024-03-12 05:44 1454

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results

SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM-101 is a humanized monoclonal antibody targeting...

2024-03-11 17:00 1883

AI Empowers Surgery: CAIR unveils its latest large multimodality model for surgery

HONG KONG, March 11, 2024 /PRNewswire/ -- As artificial intelligence technology continues to advance, it has accelerated intelligent innovation across various industries. Breakthroughs in AI technologies like GPT have gained widespread attention, especially in the healthcare sector, where they of...

2024-03-11 15:06 1407

Apollo Hospitals Unveils South Asia's First ZAP-X, Transforming Brain Tumor Care

NEW DELHI, March 11, 2024 /PRNewswire/ -- Apollo Hospitals becomes the first hospital to introduce ZAP-X Gyroscopic Radiosurgery Platform, a significant milestone as the first inSouth Asia to introduce this ground-breaking technology. ZAP-X introduces a new era in brain tumor treatment, offering ...

2024-03-11 15:00 1534

RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024

YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab ...

2024-03-11 10:36 1358

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau

-- Macau is on course to become the first of Everest's Asian territories to get etrasimod approval -- Can provide access to patients in China's Greater Bay area and rest of Asia SHANGHAI, March 11, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceu...

2024-03-11 09:00 2299

Launch of CMDF Showcase Event to Share Achievements, Promote Chinese Medicine Culture to Public and Remark a New Mileage of Chinese Medicine Development

HONG KONG, March 9, 2024 /PRNewswire/ -- In 2019, the HKSAR Government officially launched the Chinese Medicine Development Fund (CMDF) to promote the development and elevate the overall standards of the Chinese medicine (CM) sector inHong Kong. Starting from today, the CMDF will host a four-day ...

2024-03-09 18:17 2516

Innovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

ROCKVILLIE, Md. and SUZHOU, China, March 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and...

2024-03-07 11:53 2474

Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao

Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer HONG KONG and MACAO, March 7, 2024 /PRNewswire/ -- A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Phar...

2024-03-07 10:11 1980

A Global Milestone in Innovative Pancreatic Cancer Therapy

Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate. TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a memb...

2024-03-07 10:00 1767

Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance

CAESAREA, Israel, March 7, 2024 /PRNewswire/ -- Epitomee® (TASE: EPIT) announced today that onFebruary 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in theUSA, reaching a significant milestone in the company's journey. The Epitomee® capsule offers an innovative, orally adm...

2024-03-07 09:00 1499

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-03-06 19:33 1665

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment ofMark W...

2024-03-06 12:29 1702

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

SHANGHAI, March 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the fu...

2024-03-06 08:59 1689

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its op...

2024-03-06 08:45 1817

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). * The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic. S...

2024-03-06 08:30 1895

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

* Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underly...

2024-03-06 05:30 1755

IRBM Expands Global Reach in Drug Discovery with New Boston Office

Strategic Growth and Increased Visibility Set to Enhance IRBM's Leadership Position ROME, March 5, 2024 /PRNewswire/ -- IRBM, an integrated drug discovery Contract Research Organization (CRO), announces its global expansion with a new office inBoston, Massachusetts, a cornerstone for biotechnolo...

2024-03-05 20:24 1519
12345678 ... 181